Clinical trials: Pancreatic Beta Cell Function
Type 1 Diabetes Mellitus
Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset Subjects
The purpose of this study is to determine whether treatment with multiple injections of GAD-Alum will preserve the body's own (endogenous) insulin production in patients who have been recently diagnosed with type 1 diabetes…
- Trial name
- TN08 (NCT00529399)
- Testing
- GAD-Alum, GAD-Alum and Aluminum hydroxide, Aluminum hydroxide
- Where
- 15 sites in United States, Canada
- Volunteers
- 145 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Type 1
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.
- Trial name
- NCT07222332
- Testing
- Baricitinib
- Where
- 131 sites in United States, Australia and 18 more
- Volunteers
- 300 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes
Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes
Sanford Research/USD proposes to study the combination therapy of oral administration of sitagliptin and lansoprazole versus placebo for the preservation of pancreatic beta cells still present in patients with recent-onset…
- Trial name
- REPAIR-T1D (NCT01155284)
- Testing
- Sitagliptin and Lansoprazole
- Where
- 3 sites in United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Sanford Health
Type 2 Diabetes
Study of Vitamin D and Omega-3 Supplementation for Preventing Diabetes
The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is an ongoing randomized clinical trial in 25,875 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids…
- Trial name
- NCT01633177
- Testing
- Vitamin D3, Omega-3 fatty acid (fish oil)
- Where
- United States
- Volunteers
- 22,220 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Pseudohypoparathyroidism and Pseudopseudohypoparathyroidism, Pseudohypoparathyroidism Type Ia
Glucose Homeostasis in Pseudohypoparathyroidism
It is increasingly recognized that Pseudohypoparathyroidism type 1A (PHP1A) is associated with an increased risk of type 2 diabetes but the mechanism is unknown.
- Conditions
- Pseudohypoparathyroidism and Pseudopseudohypoparathyroidism, Pseudohypoparathyroidism Type Ia, Albright Hereditary Osteodystrophy
- Trial name
- NCT03761290
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Vanderbilt University Medical Center
Prediabetic State, Glucose Intolerance
Impact of Sorghum Rice on Beta-Cell Function and Insulin Resistance in Prediabetes
Prediabetes is a condition where blood sugar levels are higher than normal but not yet high enough to be diagnosed as diabetes. Without lifestyle changes, people with prediabetes often develop type 2 diabetes, a serious disease…
- Conditions
- Prediabetic State, Glucose Intolerance, Insulin Resistance, Obesity and Overweight
- Trial name
- NCT07298304
- Testing
- Sorghum Rice, white rice
- Where
- Indonesia
- Volunteers
- 26 people
- Sponsor
- Dr. Soetomo General Hospital
Diabetes Mellitus
Defining the Molecular and Physiological Mechanisms of Pancreatic Islet Cell Dysfunction Which Lead to Type 2 Diabetes
Defects in insulin secretion are central to the pathogenesis of type 2 diabetes (T2D) but the molecular basis and physiological consequences of those defects are poorly understood, impeding efforts to develop novel therapeutic…
- Trial name
- DIVA-Exeter (NCT02505308)
- Testing
- Glucose-Potentiated Arginine-Induced Insulin Secretion
- Where
- 2 sites in United Kingdom
- Volunteers
- 328 people, healthy volunteers welcome
- Sponsor
- Royal Devon and Exeter NHS Foundation Trust
Type 2 Diabetes Mellitus
An Exploratory Study of DS-8500a on Beta Cell Function Using Hyperglycemic Clamp
The objective of the study is to evaluate change in insulin secretory capacity in patients with type 2 diabetes mellitus as determined by hyperglycemic clamp after a 28-day oral administration of DS-8500a at 75 mg in a…
- Trial name
- NCT02669732
- Testing
- DS-8500a
- Where
- Japan
- Volunteers
- 21 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Type 1 Diabetes
DIATOR-Diabetes Intervention With Atorvastatin
Clinical studies have shown that immunomodulators (like Anti-CD3 antibodies) have effects on beta-cell-preservation. The lipid-lowering agent atorvastatin is also a potent immunomodulator.
- Trial name
- NCT00974740
- Testing
- Atorvastatin
- Where
- 12 sites in Germany
- Volunteers
- 63 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Type 2 Diabetes
Effect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential Therapy
Whether GLP-1 receptor agonists sequential therapy in newly diagnosed type 2 diabetic patients can further improve glycemic control, diabetes remission rate and β-cell function after the short-term insulin intensive therapy.
- Trial name
- T2DMRS (NCT02129985)
- Testing
- Exenatide, Metformin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- xiaolong zhao
Gestational Diabetes
Can Resveratrol Improve Insulin Sensitivity and Preserve Beta Cell Function Following Gestational Diabetes?
The purpose of this study is to determine if resveratrol supplementation preserves beta cell function and insulin sensitivity in post-partum women following a first diagnosis of gestational diabetes.
- Trial name
- NCT01997762
- Testing
- Resveratrol
- Where
- Canada
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- University of Manitoba
Type 2 Diabetes
Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Type 2 Diabetes Mellitus
A multi-year clinical study to improve tools for measuring the function of insulin-producing beta cells in people with type 2 diabetes mellitus.
- Trial name
- NCT01663220
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Foundation for the National Institutes of Health
Type 1 Diabetes
Encapsulated Faecal Microbiota Transplantation to Preserve Residual Beta Cell Function in Type 1 Diabetes Mellitus
In this single arm pilot study it will be investigated whether encapsulated autologous fecal microbiota transplantation may be used to halt the decline in residual beta cell function in individuals with recent onset Type 1…
- Trial name
- ENCAPSULATE (NCT05323162)
- Testing
- encapsulated autologous fecal microbiota transplantation
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Nordin Hanssen
Cystic Fibrosis-related Diabetes
β-cell Function and Insulin Sensitivity in Patients With Cystic Fibrosis
Cystic fibrosis is a genetic disorder caused by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene, leading to pulmonary infections, sinus disease, pancreatic insufficiency, hepatobiliary disease and…
- Trial name
- NCT04379726
- Testing
- therapeutic optimization
- Volunteers
- 150 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Diabetes Mellitus, Insulin-Dependent
Insulin Pump Therapy in Adolescents With Newly Diagnosed Type 1 Diabetes (T1D)
Within 4 weeks after diagnosis of type 1 diabetes, 10 subjects (pubertal males, 12-17 years old) will be randomized to either receive multiple daily injection (MDI) using Lantus insulin, or continuous subcutaneous insulin…
- Trial name
- NCT00357890
- Testing
- Insulin pump therapy, Multiple daily injections using insulin glargine + rapid acting analog
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Nemours Children's Clinic
New-onset Type 1 Diabetes Mellitus
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Antithymocyte globulin (e.g., Thymoglobulin®) is an antibody preparation that is commonly used to treat and prevent organ transplant rejection.
- Trial name
- START (NCT00515099)
- Testing
- Antithymocyte globulin
- Where
- 9 sites in United States
- Volunteers
- 58 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Type 1 Diabetes
A Phase I/II Trial to Preserve Residual Insulin Secretion in Children With Recent Onset Type 1 Diabetes by Giving Verapamil
The objective of this trial is first to evaluate safety and then the effect on preservation of residual beta cell function also clinical efficacy by treatment with Verapamil in children with recent onset Type 1 diabetes.
- Trial name
- VERADIAB-1 (NCT07199946)
- Testing
- Verapamil (Part A)
- Where
- 2 sites in Sweden
- Volunteers
- 36 people
- Sponsor
- Johnny Ludvigsson
Insulin Resistance Syndrome X, Pancreatic Beta Cell Function
Mechanism of Fatty Acid-Induced Impairment of Glucose-Stimulated Insulin Secretion
A prolonged elevation of plasma free fatty acids (FFA) impairs glucose stimulated insulin secretion. The concept of fatty acid impairment of glucose stimulated insulin secretion (lipotoxicity) has now been well accepted.
- Trial name
- NCT00188773
- Testing
- N-acetylcysteine, intralipid, heparin
- Where
- Canada
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Diabetes, Pre-diabetes
Effect of Oral L-arginine 3.32 g a Day on Oxidative Stress Influencing Beta Cell Function and Insulin Resistance.
The objective of this clinical trial is to explore whether L-arginine supplementation with 3.32g/day may enhance antioxidant defenses in overweight and obese patients with pre-diabetes and metabolic syndrome, possibly providing…
- Conditions
- Diabetes, Pre-diabetes, Metabolic Syndrome
- Trial name
- L-BIOARG (NCT06686069)
- Testing
- bioarginina zero
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Federico II University
Islets of Langerhans Transplantation, Pancreatitis, Chronic
Clinical Outcome After Total Pancreatectomy With Islet Autotransplantation
A total pancreatectomy with islet autotransplantation (TPIAT) can be performed for a number of benign indications, such as chronic pancreatitis.
- Conditions
- Islets of Langerhans Transplantation, Pancreatitis, Chronic, Diabetes Mellitus
- Trial name
- TOPPER (NCT05287737)
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- Leiden University Medical Center